Allspring Global Investments Holdings LLC Trims Holdings in Encompass Health Co. (NYSE:EHC)

Allspring Global Investments Holdings LLC trimmed its position in Encompass Health Co. (NYSE:EHC) by 31.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,713 shares of the company’s stock after selling 21,415 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Encompass Health were worth $4,199,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in Encompass Health by 0.7% in the 3rd quarter. State Street Corp now owns 3,025,769 shares of the company’s stock valued at $292,410,000 after purchasing an additional 21,329 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Encompass Health by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock worth $161,781,000 after acquiring an additional 20,547 shares during the period. Copeland Capital Management LLC lifted its holdings in shares of Encompass Health by 0.7% during the 4th quarter. Copeland Capital Management LLC now owns 1,293,098 shares of the company’s stock worth $119,418,000 after acquiring an additional 8,548 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of Encompass Health by 2,458.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company’s stock worth $83,990,000 after acquiring an additional 835,135 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Encompass Health by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 769,716 shares of the company’s stock worth $71,083,000 after acquiring an additional 2,904 shares during the period. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Stock Down 1.7 %

Shares of NYSE:EHC opened at $99.87 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a 52-week low of $73.68 and a 52-week high of $104.55. The company has a 50 day moving average of $96.00 and a two-hundred day moving average of $95.76. The company has a market capitalization of $10.06 billion, a price-to-earnings ratio of 22.39, a price-to-earnings-growth ratio of 2.36 and a beta of 0.90.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. As a group, analysts forecast that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 17th. Stockholders of record on Tuesday, April 1st will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.68%. Encompass Health’s payout ratio is currently 15.25%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on EHC. Royal Bank of Canada reiterated an “outperform” rating and set a $110.00 price objective on shares of Encompass Health in a report on Tuesday, February 11th. KeyCorp increased their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Truist Financial reiterated a “buy” rating and set a $116.00 price objective (up from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. StockNews.com upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, February 15th. Finally, Barclays raised their price target on shares of Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and an average target price of $107.67.

Insider Buying and Selling

In related news, CAO Andrew L. Price sold 5,042 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.10% of the stock is currently owned by company insiders.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.